Paper34792
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.
Weiden PL and 6 others. N Engl J Med, 1979. Cited by 1,373 papers, by iCite.
Cite this record
ConductScience Library. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. Papers, record 34792. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34792
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bone Marrow Transplantation | Major topic |
| Graft vs Host Reaction | Major topic |
| Leukemia | Major topic |
| Acute Disease | |
| Female | |
| HLA Antigens | |
| Humans | |
| Leukemia, Lymphoid | |
| Pregnancy | |
| Probability | |
| Prognosis | |
| Recurrence | |
| Remission, Spontaneous | |
| Transplantation, Homologous | |
| Transplantation, Isogeneic | |
| Twins |
Source PubMed
Cited by375
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,373 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42957220 | Suspected Donor-derived Myeloid Neoplasia After Allogeneic HSCT: A Case-based Review of Clonal Evolution. | In Vivo | 2026 | https://conductscience.org/library/papers/42957220 | PubMed |
| 42955162 | The Evolving Landscape of Reduced-Intensity Conditioning: Balancing Efficacy and Toxicity Across Hematologic Malignancies. | Curr Hematol Malig Rep | 2026 | https://conductscience.org/library/papers/42955162 | PubMed |
| 42794950 | Targeting the Epigenetic-Immune Axes in Hematologic Malignancies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42794950 | PubMed |
| 42617044 | CXCR4-dependent migratory differences between peripheral Tregs and Tcons preserve GVL while limiting GVHD after HSCT. | Blood Adv | 2026 | https://conductscience.org/library/papers/42617044 | PubMed |
| 42519395 | Pediatric AML CAR T cell therapy. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42519395 | PubMed |
| 42480219 | Long-acting pegylated interferon gamma sensitizes AML cells to killing by donor T cells. | Blood Adv | 2026 | https://conductscience.org/library/papers/42480219 | PubMed |
| 41857187 | Impact of acute GvHD severity on survival and disease relapse in pediatric patients undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia: an analysis based on the EBMT-PDWP registry. | Bone Marrow Transplant | 2026 | https://conductscience.org/library/papers/41857187 | PubMed |
| 41761243 | Therapeutic potential of cytokine-induced killer cell therapy for renal cell carcinoma and prostate cancer. | Cell Commun Signal | 2026 | https://conductscience.org/library/papers/41761243 | PubMed |
| 41566777 | Strategies to eliminate native T cell receptors for adoptive T cell therapies. | Mol Ther | 2026 | https://conductscience.org/library/papers/41566777 | PubMed |
| 41394288 | CAR T-cell therapy for neurological disorders: scientific rationale and mechanistic insights. | Ther Adv Neurol Disord | 2025 | https://conductscience.org/library/papers/41394288 | PubMed |
| 41347998 | Gene transfer and genome editing of T cells for cancer immunotherapy: from allogeneic HSCT to TCR gene editing. | Hematology Am Soc Hematol Educ Program | 2025 | https://conductscience.org/library/papers/41347998 | PubMed |
| 41091527 | Similarities and Differences Between Allogeneic Hematopoietic Cell and Organ Transplantation and What We Can Learn From Each Other to Guide Global Health Strategy. | Clin Transplant | 2025 | https://conductscience.org/library/papers/41091527 | PubMed |
| 40864984 | CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia. | Blood | 2025 | https://conductscience.org/library/papers/40864984 | PubMed |
| 40841587 | Targeting the roots of myeloid malignancies with T cell receptors. | Nat Rev Cancer | 2025 | https://conductscience.org/library/papers/40841587 | PubMed |
| 40810334 | Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation. | Br J Haematol | 2025 | https://conductscience.org/library/papers/40810334 | PubMed |
| 40488825 | Optimal GVHD Prophylaxis. | Adv Exp Med Biol | 2025 | https://conductscience.org/library/papers/40488825 | PubMed |
| 40458939 | Graft-versus-leukemia. | Haematologica | 2025 | https://conductscience.org/library/papers/40458939 | PubMed |
| 40429375 | Hematopoietic Stem Cell Transplantation: Recent Advances. | J Clin Med | 2025 | https://conductscience.org/library/papers/40429375 | PubMed |
| 40207714 | Reduced incidence of relapse and graft-versus-host disease in acute myeloid leukemia after allogeneic hematopoietic cell transplantation. | Haematologica | 2025 | https://conductscience.org/library/papers/40207714 | PubMed |
| 39766080 | Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39766080 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34792
GET https://conductscience.org/api/papers/v1/34792/cited_by?page=2